Recro Pharma, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a new development agreement with Astex Pharmaceuticals, Inc.
“We are excited to add Astex, a leading developer of novel therapeutics for cancer, to our growing list of CDMO customers,” said Bill Hirschman, vice president of sales and marketing for Recro. “The support we have been engaged to provide represents the type of durable, trusted relationship we work every day to build with our customers. We look forward to an ever-expanding partnership and wish Astex continued success.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!